Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Holding STRO?
Track your performance easily
STRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.01 - $6.13
Previous Close$4.4
Volume397.19K
Average Volume (3M)609.05K
Market Cap
$360.64M
Enterprise Value-$38.83M
Total Cash (Recent Filing)$425.99M
Total Debt (Recent Filing)$26.53M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding81,963,659
10 Day Avg. Volume647,133
30 Day Avg. Volume609,054
Standard Deviation0.19
R-Squared0.10
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.19
Price to Sales (P/S)2.13
Price to Cash Flow (P/CF)9.50
P/FCF Ratio9.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.23
Enterprise Value/Gross Profit-0.25
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$10.83Price Target Upside165.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Sutro Biopharma News
PremiumCompany Announcements
Sutro Biopharma Advances Pipeline Amid Financial Losses
PremiumCompany Announcements
Sutro Biopharma Appoints Sukhi Jagpal to Board and Audit CommitteeBulls Say, Bears Say
Bulls Say
Financial StabilityThe company has a solid cash position of $375.6MM, providing financial stability and flexibility for future developments.
Pipeline And InnovationSutro’s next-generation ADCs address the shortcomings of previous generations, enabling advancements using non-natural amino acids for more effective treatments.
Strategic CollaborationsSutro's strong track record of securing attractive collaborations through the XpressCF platform technology suggests future partnerships are well within reach.
Bears Say
Adverse Effects44% of patients experienced treatment-related adverse events leading to discontinuation, which is higher than the 38% for mirv+bev.
Clinical PerformanceSafety data was pooled, making it difficult to assess the performance of the RP2D.
Stock PerformanceShares are down -30% YTD, largely due to the lack of clinical catalysts, and are expected to remain range bound until nearer the Part 2 readout.
---
Ownership Overview
8.82% Insiders
9.83% Mutual Funds
2.85% Other Institutional Investors
68.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $2.00 and its highest was $6.13 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Currently, no data Available
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Mar 26, 2025 which is in 125 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Currently, no data Available
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 81,963,660 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Among the largest hedge funds holding Sutro Biopharma Inc’s share is Fisher Asset Management LLC. It holds Sutro Biopharma Inc’s shares valued at 795K.
---
Sutro Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.83 (165.44% Upside)
$10.83 (165.44% Upside)
Blogger Sentiment
Bullish
STRO Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 11.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
111.53%
12-Months-Change
Fundamentals
Return on Equity
-81.10%
Trailing 12-Months
Asset Growth
5.19%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
---
STRO Stock 12 Month Forecast
Average Price Target
$10.83
▲(165.44% Upside)
Technical Analysis
Best Analysts Covering STRO
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+3.78%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +3.78% per trade.
---